Previous studies have shown that simultaneously targeting two enzymes of the mevalonate pathway via dual inhibition of HMGCR by fluvastatin and farnesyl pyrophosphate synthase using zoledronic acid (Figure 1) is more effective in inhibiting the growth of human pancreatic cancer cell lines than using fluvastatin alone [40]. The gene discussed is HMGCR; the disease is familial pancreatic carcinoma.